A Phase 1/2, Open-Label, Dose-Escalation, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
Year: 2014
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: The University of Texas MD Anderson Cancer Center, University of Michigan, Cornell University, Dana-Farber Cancer Institute, University of Chicago Medical Center, University of California San Diego, Northwestern University, NS Pharma, Inc. (United States), Mayo Clinic, Mayo Clinic in Arizona
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2516498361